4-aminobenzoic acid has been researched along with Asthma, Bronchial in 8 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the anti-inflammatory effects of CHF6001 and the corticosteroid, 17-BMP, on T-cell receptor (TCR) stimulated Th1, Th2 and Th17 cytokine release from bronchoalveolar lavage (BAL) cells from mild (n = 12) and moderate asthma (n = 12) patients." | 7.91 | Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. ( Civelli, M; Facchinetti, F; Hodgson, L; Kaur, M; Singh, D; Southworth, T; Villetti, G, 2019) |
| "CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases." | 6.82 | A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. ( Barnes, PJ; Boyce, M; Collarini, S; Leaker, B; Mariotti, F; Nandeuil, MA; Santoro, D; Singh, D, 2016) |
| "This study investigated the anti-inflammatory effects of CHF6001 and the corticosteroid, 17-BMP, on T-cell receptor (TCR) stimulated Th1, Th2 and Th17 cytokine release from bronchoalveolar lavage (BAL) cells from mild (n = 12) and moderate asthma (n = 12) patients." | 3.91 | Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. ( Civelli, M; Facchinetti, F; Hodgson, L; Kaur, M; Singh, D; Southworth, T; Villetti, G, 2019) |
| "CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases." | 2.82 | A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. ( Barnes, PJ; Boyce, M; Collarini, S; Leaker, B; Mariotti, F; Nandeuil, MA; Santoro, D; Singh, D, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sabogal Piñeros, YS | 1 |
| Dekker, T | 1 |
| Smids, B | 1 |
| Majoor, CJ | 1 |
| Ravanetti, L | 1 |
| Villetti, G | 3 |
| Civelli, M | 3 |
| Facchinetti, F | 3 |
| Lutter, R | 1 |
| Southworth, T | 1 |
| Kaur, M | 1 |
| Hodgson, L | 1 |
| Singh, D | 2 |
| Armani, E | 1 |
| Amari, G | 1 |
| Rizzi, A | 1 |
| De Fanti, R | 1 |
| Ghidini, E | 1 |
| Capaldi, C | 1 |
| Carzaniga, L | 1 |
| Caruso, P | 1 |
| Guala, M | 1 |
| Peretto, I | 1 |
| La Porta, E | 1 |
| Bolzoni, PT | 1 |
| Carnini, C | 1 |
| Moretto, N | 1 |
| Patacchini, R | 1 |
| Bassani, F | 1 |
| Cenacchi, V | 1 |
| Volta, R | 1 |
| Amadei, F | 1 |
| Capacchi, S | 1 |
| Delcanale, M | 1 |
| Puccini, P | 1 |
| Catinella, S | 1 |
| Liu, RM | 1 |
| Eldridge, S | 1 |
| Watanabe, N | 1 |
| Deshane, J | 1 |
| Kuo, HC | 1 |
| Jiang, C | 1 |
| Wang, Y | 1 |
| Liu, G | 1 |
| Schwiebert, L | 1 |
| Miyata, T | 1 |
| Thannickal, VJ | 1 |
| Leaker, B | 1 |
| Boyce, M | 1 |
| Nandeuil, MA | 1 |
| Collarini, S | 1 |
| Mariotti, F | 1 |
| Santoro, D | 1 |
| Barnes, PJ | 1 |
| SIGG, K | 1 |
| Mohorn, M | 1 |
| Knüpfer, M | 1 |
| Slapke, J | 1 |
| Hummel, S | 1 |
| Wischnewsky, GG | 1 |
| Winkler, J | 1 |
2 trials available for 4-aminobenzoic acid and Asthma, Bronchial
| Article | Year |
|---|---|
A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.
Topics: Administration, Inhalation; Adult; Allergens; Asthma; Cross-Over Studies; Dose-Response Relationship | 2016 |
Protease inhibitor prevents bronchoconstriction in man.
Topics: 4-Aminobenzoic Acid; Adolescent; Adult; Aminobenzoates; Analgesics; Asthma; Asthma, Exercise-Induced | 1986 |
6 other studies available for 4-aminobenzoic acid and Asthma, Bronchial
| Article | Year |
|---|---|
Phosphodiesterase 4 inhibitors attenuate virus-induced activation of eosinophils from asthmatics without affecting virus binding.
Topics: Aminoquinolines; Asthma; Case-Control Studies; Eosinophils; Humans; Orthomyxoviridae; para-Aminobenz | 2020 |
Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients.
Topics: Adult; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Cell | 2019 |
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Benzoates; Cel | 2014 |
Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma.
Topics: Airway Remodeling; Animals; Asthma; Cytokines; Eosinophils; Female; Fibrinolysis; Ovalbumin; para-Am | 2016 |
[Therapeutic anesthesia with panthesin in asthma. angina pectoris, cardiac arrhythmia, polyarthritis, &c].
Topics: Anesthesia; Angina Pectoris; Arrhythmias, Cardiac; Arthritis; Asthma; Brugada Syndrome; Cardiac Cond | 1951 |
[Effectiveness of the calcium antagonist nifedipine and the protease inhibitor with plasmin inactivating effect para-aminomethylbenzoic acid on stress-induced bronchial asthma].
Topics: 4-Aminobenzoic Acid; Adolescent; Adult; Airway Resistance; Aminobenzoates; Antifibrinolytic Agents; | 1984 |